Drug intelligence / Profile preview

oregovomab + paclitaxel + carboplatin

Development stage: Unknown
Lead developer: CanariaBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A parenteral combination therapy of **oregovomab** (a murine monoclonal IgG1k antibody targeting CA-125/MUC16), **paclitaxel** (a microtubule stabilizer chemotherapeutic agent), and **carboplatin** (a platinum-based chemotherapeutic agent), under clinical development for advanced epithelial ovarian cancer. Oregovomab binds to the CA-125 tumor-associated antigen, enhancing its immunogenicity, activating T cell immune responses, and is hypothesized to bypass tumor-associated immune suppression when combined with cytotoxic chemotherapy. The combination aims to improve progression-free and overall survival compared to standard paclitaxel and carboplatin chemotherapy[1][3][5][7].

Brand names: OvaRex (for oregovomab)None (for combination)
Other names: oregovomab plus paclitaxel and carboplatinoregovomab/paclitaxel/carboplatin

Targets

MUC16 (Mucin-16)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on oregovomab + paclitaxel + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oregovomab + paclitaxel + carboplatin.

Explore the full profile